{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:29:15Z","timestamp":1793089755664,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T00:00:00Z","timestamp":1572652800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jtho.2018.08.2036","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T20:17:14Z","timestamp":1537906634000},"page":"1655-1667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation"],"prefix":"10.1016","volume":"13","author":[{"given":"Anne S.","family":"Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Wolf","family":"Lindwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Beyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan M.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu R.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"David H.","family":"Harpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hesdorffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julija","family":"Hmeljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.S.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Sepesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwari","family":"Sridhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szlosarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Taioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakun M.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.08.2036_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2017.04.002","article-title":"Epidemiology of environmental exposure and malignant mesothelioma","volume":"2","author":"Liu","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant Mesothelioma Mortality\u2013United States, 1999-2015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jtho.2018.08.2036_bib4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.athoracsur.2014.04.040","article-title":"Women with malignant pleural mesothelioma have a threefold better survival rate than men","volume":"98","author":"Taioli","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib6","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.08.2036_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JTO.0000000000000506","article-title":"The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada","volume":"10","author":"Baumann","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2018.08.2036_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2018.08.2036_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib12","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.08.2036_bib13","series-title":"Integrative molecular characterization of malignant pleural mesothelioma","author":"Hmeljak","year":"2018"},{"key":"10.1016\/j.jtho.2018.08.2036_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s12885-015-1362-2","article-title":"Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma","volume":"15","author":"Kalra","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","article-title":"Patient-derived xenograft establishment from human malignant pleural mesothelioma","volume":"23","author":"Wu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural\u00a0pneumonectomy versus no extra-pleural pneumonectomy\u00a0for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"Friedberg","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00002371-199809000-00007","article-title":"Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma","volume":"21","author":"Davidson","year":"1998","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jtho.2018.08.2036_bib20","first-page":"789069","article-title":"The \"Trojan horse\" approach to tumor immunotherapy: targeting the tumor microenvironment","volume":"2014","author":"Nelson","year":"2014","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib21","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1067\/mtc.2001.116560","article-title":"A\u00a0phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"Rusch","year":"2001","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","article-title":"A\u00a0feasibility study evaluating surgery for mesothelioma after radiation therapy: the \"SMART\" approach for resectable malignant pleural mesothelioma","volume":"9","author":"Cho","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2018.08.2036_bib26","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib27","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ijrobp.2011.09.027","article-title":"Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"83","author":"Rosenzweig","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2018.08.2036_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37549\/ARO1107","article-title":"Volumetric-modulated arc therapy for malignant pleural mesothelioma after pleurectomy\/decortication","volume":"5","author":"Dumane","year":"2016","journal-title":"Appl Rad Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib29","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.prro.2014.11.005","article-title":"Early experience with intensity modulated proton therapy for lung-intact mesothelioma: a case series","volume":"5","author":"Pan","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtho.2017.10.033","article-title":"Biomarker-integrated neoadjuvant dasatinib trial in resectable malignant pleural mesothelioma","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib31","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A\u00a0randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib32","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib34","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.12.004","article-title":"A\u00a0phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario Clinical Oncology Group","volume":"104","author":"Laurie","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib36","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A\u00a0phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib38","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib39","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A\u00a0phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.08.2036_bib43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2018.08.2036_bib44","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib45","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1200\/JCO.2018.36.15_suppl.8514","article-title":"SWOG 0905: a randomized phase II study of cediranib versus placebo in combination with cisplatin-pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (MPM) [abstract]","volume":"36","author":"Tsao","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib46","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib48","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib49","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2018.08.2036_bib50","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib51","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.celrep.2016.02.023","article-title":"Large-scale profiling of kinase dependencies in cancer cell lines","volume":"14","author":"Campbell","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2018.08.2036_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib53","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib55","doi-asserted-by":"crossref","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2018.08.2036_bib56","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib57","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","article-title":"Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss-driven tumorigenesis","volume":"16","author":"Cooper","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.08.2036_bib58","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib59","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2018.08.2036_bib60","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1513\/AnnalsATS.201506-315LE","article-title":"Spontaneous regression of malignant pleural mesothelioma in a patient with new-onset inflammatory arthropathy","volume":"12","author":"Moser","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jtho.2018.08.2036_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0169-5002(00)00217-8","article-title":"Localised spontaneous regression in mesothelioma\u2013possible immunological mechanism","volume":"32","author":"Robinson","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib62","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.LBA8507","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib63","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21037\/tlcr.2017.04.01","article-title":"Immunotherapy and radiation therapy for malignant pleural mesothelioma","volume":"6","author":"Alley","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib64","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2018.08.2036_bib65","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib66","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1158\/1078-0432.CCR-15-2246","article-title":"Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer","volume":"22","author":"Mansfield","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib67","doi-asserted-by":"crossref","first-page":"e1356146","DOI":"10.1080\/2162402X.2017.1356146","article-title":"Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma","volume":"6","author":"Terra","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2018.08.2036_bib68","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1016\/j.jtho.2016.11.347","article-title":"Prospective immunogenomic profiling of non-small cell lung cancer - the ICON Project","volume":"12","author":"Sepesi","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e20034","article-title":"Immunogenomic profiling of non-small cell lung cancer: the ICON project","volume":"35","author":"Sepesi","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib70","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant\u00a0mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib72","doi-asserted-by":"crossref","first-page":"e1273302","DOI":"10.1080\/2162402X.2016.1273302","article-title":"CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy","volume":"6","author":"Chen","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2018.08.2036_bib73","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity","volume":"5","author":"Leshem","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib75","first-page":"S195","article-title":"Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine","volume":"10","author":"Hassan","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib76","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib77","doi-asserted-by":"crossref","first-page":"82700","DOI":"10.18632\/oncotarget.12408","article-title":"Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers","volume":"7","author":"Bononi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.08.2036_bib78","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib79","doi-asserted-by":"crossref","first-page":"e0135331","DOI":"10.1371\/journal.pone.0135331","article-title":"Two different serum MiRNA signatures correlate with the clinical outcome and histological subtype in pleural malignant mesothelioma patients","volume":"10","author":"Lamberti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2018.08.2036_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2018.08.2036_bib81","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2018.08.2036_bib82","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.7314\/APJCP.2015.16.4.1403","article-title":"Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma","volume":"16","author":"Kaya","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jtho.2018.08.2036_bib83","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib84","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.08.2036_bib85","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/MCG.0b013e318297fa65","article-title":"Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma","volume":"47","author":"Tabata","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib86","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib87","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib88","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib89","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib90","doi-asserted-by":"crossref","first-page":"12298","DOI":"10.1038\/srep12298","article-title":"Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations","volume":"5","author":"Lesterhuis","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2018.08.2036_bib91","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chest.2016.10.007","article-title":"Immunotherapy for lung malignancies: from gene sequencing to novel therapies","volume":"151","author":"Chee","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2018.08.2036_bib92","doi-asserted-by":"crossref","first-page":"e1011492","DOI":"10.1080\/2162402X.2015.1011492","article-title":"Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen","volume":"4","author":"Creaney","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2018.08.2036_bib93","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0169-5002(03)00292-7","article-title":"Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma","volume":"43","author":"van Klaveren","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.08.2036_bib94","doi-asserted-by":"crossref","first-page":"W125","DOI":"10.2214\/AJR.09.3519","article-title":"Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes","volume":"195","author":"Gill","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib95","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1148\/radiol.12110872","article-title":"Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging\u2014initial experience","volume":"263","author":"Coolen","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2018.08.2036_bib96","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A\u00a0novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.08.2036_bib97","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jtho.2018.08.2036_bib98","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.semtcvs.2009.06.011","article-title":"Current trends in radiologic management of malignant pleural mesothelioma","volume":"21","author":"Gill","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib99","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","article-title":"Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma","volume":"115","author":"Pass","year":"1998","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.08.2036_bib100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2214\/AJR.11.7015","article-title":"Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume","volume":"198","author":"Gill","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib101","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American Multicenter Volumetric CT Study for clinical staging of malignant pleural mesothelioma: feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.08.2036_bib103","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jogoh.2017.02.006","article-title":"Quality assessment of pelvic ultrasound for uterine myoma according to the CNGOF guidelines","volume":"46","author":"Perrot","year":"2017","journal-title":"J\u00a0Gynecol Obstet Hum Reprod"},{"key":"10.1016\/j.jtho.2018.08.2036_bib104","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2017-0152","article-title":"Oncology drug approvals: evaluating endpoints and evidence in an\u00a0era of breakthrough therapies","volume":"22","author":"Blumenthal","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2018.08.2036_bib105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418331216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418331216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T11:26:49Z","timestamp":1693913209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418331216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":105,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1556086418331216"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2036","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}